0000946563--12-31 2022 Q3 false P10Y 0000946563 us-gaap:TreasuryStockMember 2022-01-01 2022-09-30 0000946563 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000946563 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000946563 rvp:RepurchasePlanMember 2021-06-04 0000946563 rvp:RepurchasePlanMember 2021-06-04 2022-04-14 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0000946563 us-gaap:TreasuryStockMember 2022-09-30 0000946563 us-gaap:RetainedEarningsMember 2022-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000946563 us-gaap:TreasuryStockMember 2022-06-30 0000946563 us-gaap:RetainedEarningsMember 2022-06-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000946563 2022-06-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000946563 us-gaap:TreasuryStockMember 2021-12-31 0000946563 us-gaap:RetainedEarningsMember 2021-12-31 0000946563 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000946563 us-gaap:TreasuryStockMember 2021-09-30 0000946563 us-gaap:RetainedEarningsMember 2021-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000946563 us-gaap:TreasuryStockMember 2021-06-30 0000946563 us-gaap:RetainedEarningsMember 2021-06-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000946563 2021-06-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000946563 us-gaap:RetainedEarningsMember 2020-12-31 0000946563 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:SyringesMember country:US 2022-07-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:OtherProductsMember country:US 2022-07-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:EasyPointNeedlesMember country:US 2022-07-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:BloodCollectionProductsMember country:US 2022-07-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:SyringesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-07-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:OtherProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-07-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:EasyPointNeedlesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-07-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:BloodCollectionProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-07-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-07-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:OtherProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-07-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember country:US 2022-07-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-07-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-07-01 2022-09-30 0000946563 rvp:SyringesMember 2022-07-01 2022-09-30 0000946563 rvp:OtherProductsMember 2022-07-01 2022-09-30 0000946563 rvp:EasyPointNeedlesMember 2022-07-01 2022-09-30 0000946563 rvp:BloodCollectionProductsMember 2022-07-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:SyringesMember country:US 2022-01-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:OtherProductsMember country:US 2022-01-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:EasyPointNeedlesMember country:US 2022-01-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:BloodCollectionProductsMember country:US 2022-01-01 2022-09-30 0000946563 rvp:U.s.GovernmentMember rvp:SyringesMember country:US 2022-01-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:SyringesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-01-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:OtherProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-01-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:EasyPointNeedlesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-01-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:BloodCollectionProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-01-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-01-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:OtherProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-01-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:EasyPointNeedlesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-01-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember country:US 2022-01-01 2022-09-30 0000946563 rvp:U.s.GovernmentMember country:US 2022-01-01 2022-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2022-01-01 2022-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2022-01-01 2022-09-30 0000946563 rvp:SyringesMember 2022-01-01 2022-09-30 0000946563 rvp:OtherProductsMember 2022-01-01 2022-09-30 0000946563 rvp:EasyPointNeedlesMember 2022-01-01 2022-09-30 0000946563 rvp:BloodCollectionProductsMember 2022-01-01 2022-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:SyringesMember country:US 2021-07-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:OtherProductsMember country:US 2021-07-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:EasyPointNeedlesMember country:US 2021-07-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:BloodCollectionProductsMember country:US 2021-07-01 2021-09-30 0000946563 rvp:U.s.GovernmentMember rvp:SyringesMember country:US 2021-07-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:SyringesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-07-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:OtherProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-07-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:EasyPointNeedlesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-07-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:BloodCollectionProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-07-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-07-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:EasyPointNeedlesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-07-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:BloodCollectionProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-07-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember country:US 2021-07-01 2021-09-30 0000946563 rvp:U.s.GovernmentMember country:US 2021-07-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-07-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-07-01 2021-09-30 0000946563 rvp:SyringesMember 2021-07-01 2021-09-30 0000946563 rvp:OtherProductsMember 2021-07-01 2021-09-30 0000946563 rvp:EasyPointNeedlesMember 2021-07-01 2021-09-30 0000946563 rvp:BloodCollectionProductsMember 2021-07-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:SyringesMember country:US 2021-01-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:OtherProductsMember country:US 2021-01-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:EasyPointNeedlesMember country:US 2021-01-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember rvp:BloodCollectionProductsMember country:US 2021-01-01 2021-09-30 0000946563 rvp:U.s.GovernmentMember rvp:SyringesMember country:US 2021-01-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:SyringesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-01-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:OtherProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-01-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:EasyPointNeedlesMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-01-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:BloodCollectionProductsMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-01-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:SyringesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-01-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:OtherProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-01-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:EasyPointNeedlesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-01-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:BloodCollectionProductsMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-01-01 2021-09-30 0000946563 rvp:UnitedStatesCustomersExcludingUnitedStatesGovernmentMember country:US 2021-01-01 2021-09-30 0000946563 rvp:U.s.GovernmentMember country:US 2021-01-01 2021-09-30 0000946563 rvp:InternationalCustomersExcludingNorthAndSouthAmericaMember rvp:InternationalExcludingNorthAndSouthAmericaMember 2021-01-01 2021-09-30 0000946563 rvp:CustomersInNorthAndSouthAmericaExcludingUnitedStatesMember rvp:NorthAndSouthAmericaExcludingUnitedStatesMember 2021-01-01 2021-09-30 0000946563 rvp:SyringesMember 2021-01-01 2021-09-30 0000946563 rvp:OtherProductsMember 2021-01-01 2021-09-30 0000946563 rvp:EasyPointNeedlesMember 2021-01-01 2021-09-30 0000946563 rvp:BloodCollectionProductsMember 2021-01-01 2021-09-30 0000946563 rvp:TechnologyInvestmentAgreementMember rvp:OriginalAgreementMember 2021-05-01 2021-05-31 0000946563 rvp:TechnologyInvestmentAgreementMember rvp:AmendmentToAgreementMember 2021-05-01 2021-05-31 0000946563 rvp:TechnologyInvestmentAgreementMember 2021-05-01 2021-05-31 0000946563 rvp:TechnologyInvestmentAgreementMember 2020-07-01 2020-07-01 0000946563 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-09-30 0000946563 srt:MinimumMember us-gaap:EquipmentMember 2022-01-01 2022-09-30 0000946563 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-09-30 0000946563 srt:MaximumMember us-gaap:EquipmentMember 2022-01-01 2022-09-30 0000946563 us-gaap:BuildingMember 2022-01-01 2022-09-30 0000946563 us-gaap:BuildingImprovementsMember 2022-01-01 2022-09-30 0000946563 srt:WarehouseMember 2022-01-01 2022-09-30 0000946563 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2022-09-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2022-09-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember 2021-12-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember 2021-12-31 0000946563 us-gaap:PreferredClassBMember 2022-09-30 0000946563 us-gaap:PreferredClassBMember 2021-12-31 0000946563 us-gaap:NonUsMember 2022-09-30 0000946563 country:US 2022-09-30 0000946563 us-gaap:NonUsMember 2021-12-31 0000946563 country:US 2021-12-31 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2022-09-30 0000946563 us-gaap:FairValueInputsLevel1Member rvp:MutualFundsAndExchangeTradedFundsMember 2022-09-30 0000946563 us-gaap:FairValueInputsLevel1Member rvp:EquitySecuritiesExcludingMutualFundsAndExchangeTradedFundsMember 2022-09-30 0000946563 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2021-12-31 0000946563 us-gaap:FairValueInputsLevel1Member rvp:MutualFundsAndExchangeTradedFundsMember 2021-12-31 0000946563 us-gaap:FairValueInputsLevel1Member rvp:EquitySecuritiesExcludingMutualFundsAndExchangeTradedFundsMember 2021-12-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-10-01 2022-10-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-10-01 2022-10-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-07-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-07-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-04-30 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-04-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-01-31 0000946563 rvp:SeriesThreeConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-01-31 0000946563 rvp:SeriesOneConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-01-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-10-01 2021-10-31 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-04-30 0000946563 rvp:SeriesTwoConvertibleClassBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-01-31 0000946563 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000946563 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000946563 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000946563 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000946563 rvp:PaycheckProtectionProgramLoanMember us-gaap:CommercialPaperMember 2020-04-17 0000946563 2021-05-13 2021-05-13 0000946563 us-gaap:RoyaltyMember 2022-07-01 2022-09-30 0000946563 us-gaap:ProductMember 2022-07-01 2022-09-30 0000946563 us-gaap:RoyaltyMember 2022-01-01 2022-09-30 0000946563 us-gaap:ProductMember 2022-01-01 2022-09-30 0000946563 us-gaap:RoyaltyMember 2021-07-01 2021-09-30 0000946563 us-gaap:ProductMember 2021-07-01 2021-09-30 0000946563 us-gaap:RoyaltyMember 2021-01-01 2021-09-30 0000946563 us-gaap:ProductMember 2021-01-01 2021-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2022-07-01 2022-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2021-07-01 2021-09-30 0000946563 rvp:SignificantCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000946563 country:CN us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-09-30 0000946563 2021-09-30 0000946563 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0000946563 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000946563 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000946563 2020-07-01 2020-07-01 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000946563 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000946563 2022-02-01 2022-02-28 0000946563 2021-02-01 2021-02-28 0000946563 2021-05-01 2021-05-31 0000946563 2020-12-31 0000946563 2022-07-01 2022-09-30 0000946563 2021-07-01 2021-09-30 0000946563 rvp:MutualFundsAndExchangeTradedFundsMember 2022-09-30 0000946563 us-gaap:EquitySecuritiesMember 2022-09-30 0000946563 rvp:EquitySecuritiesExcludingMutualFundsAndExchangeTradedFundsMember 2022-09-30 0000946563 us-gaap:EquitySecuritiesMember 2021-12-31 0000946563 rvp:MutualFundsAndExchangeTradedFundsMember 2021-12-31 0000946563 rvp:EquitySecuritiesExcludingMutualFundsAndExchangeTradedFundsMember 2021-12-31 0000946563 2022-03-31 0000946563 2021-12-31 0000946563 us-gaap:PreferredClassBMember 2021-06-01 2021-06-30 0000946563 2022-11-01 2022-11-01 0000946563 2020-01-01 2020-12-31 0000946563 2021-01-01 2021-09-30 0000946563 2022-09-30 0000946563 srt:MinimumMember 2022-01-01 2022-09-30 0000946563 srt:MaximumMember 2022-01-01 2022-09-30 0000946563 2022-11-01 0000946563 2022-01-01 2022-09-30 xbrli:shares iso4217:USD xbrli:pure rvp:item rvp:stockholder rvp:customer iso4217:USD xbrli:shares

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 10-Q

​

(Mark One)

​

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended September 30, 2022

​

or

​

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

​

For the transition period from to

​

Commission file number: 001-16465

​

Retractable Technologies, Inc.

(Exact name of registrant as specified in its charter)

​

​

| ​ |
Texas |  | 75-2599762
(State or other jurisdiction of incorporation or organization) | ​ | (I.R.S. Employer Identification No.)
​ | ​ | ​
511 Lobo Lane | ​ | ​
Little Elm, Texas | ​ | 75068-5295
(Address of principal executive offices) | ​ | (Zip Code)

​

(972) 294-1010

(Registrant’s telephone number, including area code)

​

(Former name, former address, and former fiscal year, if changed since last report)

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock | RVP | NYSE American

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​ | ​ | ​ | ​
Large accelerated filer | ☐ | Accelerated filer | ☐
​ | ​ | ​ | ​
Non-accelerated filer | ☑ | Smaller reporting company | ☑
​ | ​ | Emerging growth company | ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

​

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

​

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ◻ No

​

APPLICABLE ONLY TO CORPORATE ISSUERS

​

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 32,937,159 shares of Common Stock outstanding, excluding 1,087,845 treasury shares, on November 1, 2022.

​

​

​

​

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

FORM 10-Q

For the Quarterly Period Ended September 30, 2022

TABLE OF CONTENTS

​

​ | PART I – FINANCIAL INFORMATION | ​ | ​
​ | ​ | ​ | ​
Item 1. | Financial Statements |  | 1
​ | CONDENSED BALANCE SHEETS | ​ | 1
​ | CONDENSED STATEMENTS OF OPERATIONS | ​ | 2
​ | CONDENSED STATEMENTS OF CASH FLOWS | ​ | 3
​ | CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY | ​ | 4
​ | NOTES TO CONDENSED FINANCIAL STATEMENTS | ​ | 5
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | ​ | 17
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | ​ | 23
Item 4. | Controls and Procedures | ​ | 23
​ | ​ | ​ | ​
​ | PART II—OTHER INFORMATION | ​ | ​
​ | ​ | ​ | ​
Item 1. | Legal Proceedings | ​ | 23
Item 1A. | Risk Factors | ​ | 23
Item 6. | Exhibits | ​ | 24
SIGNATURES | ​ | 24

​

​

​

​

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1.Financial Statements.

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED BALANCE SHEETS

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2022 |  | December 31, 2021
ASSETS | ​ | ​ | ​ | ​ | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 13,417,554 | ​ | $ | 29,162,913
Accounts receivable, net | ​ |  | 17,901,973 | ​ |  | 34,859,505
Receivable from Technology Investment Agreement (TIA) | ​ | ​ | 1,836,826 | ​ | ​ | 5,924,136
Investments in equity securities, at fair value | ​ | ​ | 26,314,374 | ​ | ​ | 13,268,986
Inventories | ​ |  | 18,519,177 | ​ |  | 20,589,919
Income taxes receivable | ​ | ​ | 13,027,101 | ​ | ​ | —
Other current assets | ​ |  | 767,281 | ​ |  | 701,969
Total current assets | ​ |  | 91,784,286 | ​ |  | 104,507,428
​ | ​ | ​ | ​ | ​ | ​ | ​
Property, plant, and equipment, net | ​ |  | 98,821,412 | ​ |  | 87,925,651
Deferred tax asset | ​ | ​ | 9,971,960 | ​ | ​ | 13,865,834
Other assets | ​ |  | 5,674 | ​ |  | 5,675
Total assets | ​ | $ | 200,583,332 | ​ | $ | 206,304,588
​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ | $ | 8,132,977 | ​ | $ | 20,404,573
Current portion of long-term debt | ​ |  | 291,111 | ​ |  | 289,114
Accrued compensation | ​ |  | 817,064 | ​ |  | 1,056,656
Dividends payable | ​ |  | 1,417,937 | ​ |  | 1,438,371
Accrued royalties to shareholder | ​ |  | 1,488,811 | ​ |  | 3,450,684
Other accrued liabilities | ​ |  | 2,845,672 | ​ |  | 3,725,527
Income taxes payable | ​ |  | — | ​ |  | 4,959,878
Total current liabilities | ​ |  | 14,993,572 | ​ |  | 35,324,803
​ | ​ | ​ | ​ | ​ | ​ | ​
Other long-term liabilities | ​ | ​ | 75,006,588 | ​ | ​ | 69,996,330
Long-term debt, net of current maturities | ​ |  | 1,598,537 | ​ |  | 1,814,194
Total liabilities | ​ |  | 91,598,697 | ​ |  | 107,135,327
​ | ​ | ​ | ​ | ​ | ​ | ​
Commitments and contingencies – see Note 8 | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Stockholders’ equity: | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, $1 par value: | ​ | ​ | ​ | ​ | ​ | ​
Class B; authorized: 5,000,000 shares | ​ | ​ | ​ | ​ | ​ | ​
Series II, Class B | ​ |  | 156,200 | ​ |  | 156,200
Series III, Class B | ​ |  | 76,245 | ​ |  | 76,245
Common Stock, no par value | ​ |  | — | ​ |  | —
Additional paid-in capital | ​ |  | 66,472,660 | ​ |  | 63,024,888
Retained earnings | ​ |  | 50,368,208 | ​ |  | 41,182,429
Common stock in treasury – at cost | ​ | ​ | (8,088,678) | ​ | ​ | (5,270,501)
Total stockholders’ equity | ​ |  | 108,984,635 | ​ |  | 99,169,261
Total liabilities and stockholders’ equity | ​ | $ | 200,583,332 | ​ | $ | 206,304,588

​

See accompanying notes to condensed unaudited financial statements

​

1

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Three Months | ​ | Nine Months | ​ | Nine Months | ​
​ |  | September 30, 2022 |  | September 30, 2021 |  | September 30, 2022 |  | September 30, 2021 | ​
Sales, net | ​ | $ | 23,061,285 | ​ | $ | 36,356,047 | ​ | $ | 82,140,204 | ​ | $ | 128,926,716 | ​
Cost of sales: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of manufactured product | ​ |  | 16,835,848 | ​ |  | 20,663,651 | ​ |  | 53,225,651 | ​ |  | 60,074,349 | ​
Royalty expense to shareholder | ​ |  | 1,488,811 | ​ |  | 2,297,527 | ​ |  | 4,963,406 | ​ |  | 7,819,529 | ​
Total cost of sales | ​ |  | 18,324,659 | ​ |  | 22,961,178 | ​ |  | 58,189,057 | ​ |  | 67,893,878 | ​
Gross profit | ​ |  | 4,736,626 | ​ |  | 13,394,869 | ​ |  | 23,951,147 | ​ |  | 61,032,838 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Sales and marketing | ​ |  | 1,174,675 | ​ |  | 1,020,244 | ​ |  | 3,258,435 | ​ |  | 3,398,905 | ​
Research and development | ​ |  | 105,749 | ​ |  | 199,200 | ​ |  | 407,675 | ​ |  | 747,525 | ​
General and administrative | ​ |  | 4,146,821 | ​ |  | 4,209,836 | ​ |  | 13,311,488 | ​ |  | 12,824,957 | ​
Total operating expenses | ​ |  | 5,427,245 | ​ |  | 5,429,280 | ​ |  | 16,977,598 | ​ |  | 16,971,387 | ​
Income (loss) from operations | ​ |  | (690,619) | ​ |  | 7,965,589 | ​ |  | 6,973,549 | ​ |  | 44,061,451 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gain on forgiveness of PPP loan | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,377,652 | ​
Other income - TIA | ​ | ​ | 861,850 | ​ | ​ | — | ​ | ​ | 1,954,404 | ​ | ​ | — | ​
Unrealized loss on equity securities | ​ | ​ | (615,215) | ​ | ​ | (373,574) | ​ | ​ | (1,187,629) | ​ | ​ | — | ​
Interest and other income | ​ |  | 105,661 | ​ |  | 54,911 | ​ |  | 201,152 | ​ |  | 1,014,348 | ​
Interest expense | ​ |  | (40,273) | ​ |  | (52,886) | ​ |  | (125,746) | ​ |  | (172,668) | ​
Income (loss) before income taxes | ​ |  | (378,596) | ​ |  | 7,594,040 | ​ |  | 7,815,730 | ​ |  | 46,280,783 | ​
Provision (benefit) for income taxes | ​ |  | (5,763,850) | ​ |  | 1,072,155 | ​ |  | (1,544,383) | ​ |  | 11,140,889 | ​
Net income | ​ |  | 5,385,254 | ​ |  | 6,521,885 | ​ |  | 9,360,113 | ​ |  | 35,139,894 | ​
Preferred Stock dividend requirements | ​ |  | (58,111) | ​ |  | (59,111) | ​ |  | (174,333) | ​ |  | (183,219) | ​
Net income applicable to common shareholders | ​ | $ | 5,327,143 | ​ | $ | 6,462,774 | ​ | $ | 9,185,780 | ​ | $ | 34,956,675 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic earnings per share | ​ | $ | 0.16 | ​ | $ | 0.19 | ​ | $ | 0.28 | ​ | $ | 1.03 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Diluted earnings per share | ​ | $ | 0.16 | ​ | $ | 0.19 | ​ | $ | 0.28 | ​ | $ | 1.02 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average common shares outstanding: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ |  | 32,936,959 | ​ |  | 33,883,684 | ​ |  | 33,049,411 | ​ |  | 33,950,742 | ​
Diluted | ​ |  | 33,229,866 | ​ |  | 34,262,681 | ​ |  | 33,358,225 | ​ |  | 34,330,967 | ​

​

See accompanying notes to condensed unaudited financial statements

​

2

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months | ​ | Nine Months | ​
​ | ​ | Ended | ​ | Ended | ​
​ |  | September 30, 2022 |  | September 30, 2021 | ​
Cash flows from operating activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 9,360,113 | ​ | $ | 35,139,894 | ​
Adjustments to reconcile net income to net cash provided by operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | 2,984,785 | ​ |  | 702,384 | ​
Net unrealized (gain) loss on investments | ​ | ​ | 1,187,629 | ​ | ​ | (816,150) | ​
Realized loss on investments | ​ | ​ | 38,378 | ​ | ​ | — | ​
Accreted interest | ​ | ​ | 46,957 | ​ | ​ | 83,282 | ​
Deferred taxes | ​ | ​ | 3,893,874 | ​ | ​ | (8,514,068) | ​
Provision for doubtful accounts | ​ |  | — | ​ |  | 146,395 | ​
Share-based compensation | ​ | ​ | 3,433,972 | ​ | ​ | 2,503,152 | ​
Gain on forgiveness of PPP loan | ​ | ​ | — | ​ | ​ | (1,377,652) | ​
(Increase) decrease in operating assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable | ​ |  | 16,957,532 | ​ |  | (9,055,116) | ​
Inventories | ​ |  | 2,070,742 | ​ |  | (8,462,118) | ​
Other current assets | ​ |  | (65,312) | ​ |  | (83,512) | ​
Prepaid estimated taxes | ​ | ​ | (13,027,101) | ​ | ​ | — | ​
Other assets | ​ | ​ | — | ​ | ​ | 38,892 | ​
Increase (decrease) in operating liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ |  | (12,271,594) | ​ |  | 8,154,409 | ​
Accrued liabilities | ​ |  | (3,067,833) | ​ |  | 1,490,008 | ​
Income taxes payable | ​ |  | (4,959,878) | ​ |  | (1,820,078) | ​
Net cash provided by operating activities | ​ |  | 6,582,264 | ​ |  | 18,129,722 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from investing activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Purchase of property, plant, and equipment | ​ |  | (13,880,546) | ​ |  | (46,511,859) | ​
Purchase of equity securities | ​ | ​ | (16,196,164) | ​ | ​ | (4,685,960) | ​
Proceeds from the sales of equity securities | ​ | ​ | 1,924,769 | ​ | ​ | — | ​
Net cash used by investing activities | ​ |  | (28,151,941) | ​ |  | (51,197,819) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from financing activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Repayments of long-term debt | ​ |  | (213,661) | ​ |  | (206,310) | ​
Proceeds from Technology Investment Agreement (TIA) | ​ | ​ | 10,138,234 | ​ | ​ | 39,848,368 | ​
Proceeds from the exercise of stock options | ​ |  | 13,800 | ​ |  | 48,600 | ​
Payment of preferred stock redemption price payable | ​ | ​ | — | ​ | ​ | (101,250) | ​
Payment of preferred stock repurchase payable | ​ | ​ | (1,101,110) | ​ | ​ | (1,101,110) | ​
Payment of preferred stock dividends | ​ |  | (194,768) | ​ |  | (3,784,394) | ​
Repurchase of common stock | ​ | ​ | (2,818,177) | ​ | ​ | (2,839,326) | ​
Net cash provided by financing activities | ​ |  | 5,824,318 | ​ |  | 31,864,578 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net decrease in cash and cash equivalents | ​ |  | (15,745,359) | ​ |  | (1,203,519) | ​
Cash and cash equivalents at: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beginning of period | ​ |  | 29,162,913 | ​ |  | 17,566,682 | ​
End of period | ​ | $ | 13,417,554 | ​ | $ | 16,363,163 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental schedule of cash flow information: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest paid | ​ | $ | 78,789 | ​ | $ | 89,386 | ​
Income taxes paid | ​ | $ | 12,323,857 | ​ | $ | 21,068,540 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental schedule of noncash investing and financing activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Preferred dividends declared, not paid | ​ | $ | 1,417,937 | ​ | $ | 1,399,744 | ​
Conversion of preferred stock to common stock | ​ | $ | — | ​ | $ | 26,500 | ​
Amounts receivable under Technology Investment Agreement (TIA) | ​ | $ | 1,836,826 | ​ | $ | (3,014,325) | ​
Preferred stock repurchase payable | ​ | $ | 1,084,795 | ​ | $ | — | ​

​

See accompanying notes to condensed unaudited financial statements

​

3

Table of Contents

RETRACTABLE TECHNOLOGIES, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(unaudited)

​

The following shows the changes in stockholders’ equity for the three-month period ended September 30, 2022:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Series II |  | Series III |  | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Class B | ​ | Class B | ​ | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | ​ | Preferred | ​ | Preferred | ​ | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | ​ | Stock | ​ | Stock | ​ | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at June 30, 2022 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 65,312,124 | ​ | $ | 45,041,065 | ​ | $ | (8,088,678) | ​ | $ | 102,496,956
Stock Option Exercises | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 3,300 | ​ |  | — | ​ |  | — | ​ |  | 3,300
Dividends | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (58,111) | ​ |  | — | ​ |  | (58,111)
Stock Option Compensation | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,157,236 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,157,236
Net Income | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 5,385,254 | ​ |  | — | ​ |  | 5,385,254
Balance at September 30, 2022 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 66,472,660 | ​ | $ | 50,368,208 | ​ | $ | (8,088,678) | ​ | $ | 108,984,635

​

The following shows the changes in stockholders’ equity for the three-month period ended September 30, 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ | Series II |  | Series III | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | Class B | ​ | Class B | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | Preferred | ​ | Preferred | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | Stock | ​ | Stock | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at June 30, 2021 | ​ | $ | — | $ | 156,200 | ​ | $ | 80,245 | $ | 60,706,417 | ​ | $ | 13,853,792 | ​ | $ | (154,424) | ​ | $ | 74,642,230
Dividends | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | (39,050) | ​ | ​ | — | ​ |  | (39,050)
Stock Option Compensation | ​ | ​ | — | ​ | — | ​ | ​ | — | ​ | 1,157,236 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,157,236
Repurchase of Common Stock - at cost | ​ | ​ | — | ​ | — | ​ | ​ | — | ​ | — | ​ | ​ | — | ​ | ​ | (2,684,902) | ​ | ​ | (2,684,902)
Net Income | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | 6,521,885 | ​ | ​ | — | ​ |  | 6,521,885
Balance at September 30, 2021 | ​ | $ | — | $ | 156,200 | ​ | $ | 80,245 | $ | 61,863,653 | ​ | $ | 20,336,627 | ​ | $ | (2,839,326) | ​ | $ | 79,597,399

​

The following shows the changes in stockholders’ equity for the nine-month period ended September 30, 2022:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Series II |  | Series III |  | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Class B | ​ | Class B | ​ | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | ​ | Preferred | ​ | Preferred | ​ | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | ​ | Stock | ​ | Stock | ​ | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at December 31, 2021 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 63,024,888 | ​ | $ | 41,182,429 | ​ | $ | (5,270,501) | ​ | $ | 99,169,261
Stock Option Exercises | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 13,800 | ​ |  | — | ​ |  | — | ​ |  | 13,800
Dividends | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (174,334) | ​ |  | — | ​ |  | (174,334)
Stock Option Compensation | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,433,972 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,433,972
Repurchase of Common Stock – at cost | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (2,818,177) | ​ | ​ | (2,818,177)
Net Income | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 9,360,113 | ​ |  | — | ​ |  | 9,360,113
Balance at September 30, 2022 | ​ | $ | — | ​ | $ | 156,200 | ​ | $ | 76,245 | ​ | $ | 66,472,660 | ​ | $ | 50,368,208 | ​ | $ | (8,088,678) | ​ | $ | 108,984,635

​

​

The following shows the changes in stockholders’ equity for the nine-month period ended September 30, 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ | Series II |  | Series III | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
​ | ​ | ​ | ​ | Class B | ​ | Class B | Additional | ​ | ​ | ​ | ​ | Treasury | ​ | ​ | ​
​ | ​ | Common | Preferred | ​ | Preferred | Paid-In | ​ | Retained | ​ | Stock – | ​ | ​ | ​
​ | ​ | Stock | Stock | ​ | Stock | Capital | ​ | Earnings | ​ | at cost | ​ | Total
Balance at December 31, 2020 | ​ | $ | — | $ | 156,200 | ​ | $ | 106,745 | $ | 59,285,401 | ​ | $ | (9,668,221) | ​ | $ | — | ​ | $ | 49,880,125
Conversion of Preferred Stock into Common Stock | ​ | ​ | — | ​ | — | ​ | ​ | (26,500) | ​ | 26,500 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Stock Option Exercises | ​ |  | — |  | — | ​ |  | — |  | 48,600 | ​ |  | — | ​ | ​ | — | ​ |  | 48,600
Dividends | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | (5,135,046) | ​ | ​ | — | ​ |  | (5,135,046)
Stock Option Compensation | ​ | ​ | — | ​ | — | ​ | ​ | — | ​ | 2,503,152 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,503,152
Repurchase of Common Stock - at cost | ​ | ​ | — | ​ | — | ​ | ​ | — | ​ | — | ​ | ​ | — | ​ | ​ | (2,839,326) | ​ | ​ | (2,839,326)
Net Income | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | 35,139,894 | ​ | ​ | — | ​ |  | 35,139,894
Balance at September 30, 2021 | ​ | $ | — | $ | 156,200 | ​ | $ | 80,245 | $ | 61,863,653 | ​ | $ | 20,336,627 | ​ | $ | (2,839,326) | ​ | $ | 79,597,399

​

See accompanying notes to condensed unaudited financial statements

4

Table of Contents

​

​

RETRACTABLE TECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

1. BUSINESS OF THE COMPANY AND BASIS OF PRESENTATION

Business of the Company

Retractable Technologies, Inc. (the “Company”) was incorporated in Texas on May 9, 1994, and designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The Company began to develop its manufacturing operations in 1995. The Company’s manufacturing and administrative facilities are located in Little Elm, Texas. The Company’s products are the VanishPoint® 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the blood collection tube holder; the small diameter tube adapter; the allergy tray; the IV safety catheter; the Patient Safe® syringes; the Patient Safe® Luer Cap; the VanishPoint® Blood Collection Set; and the EasyPoint® needle as well as a standard 3mL syringe packaged with an EasyPoint® needle. The Company also sells VanishPoint® autodisable syringes in the international market in addition to the Company’s other products.

Basis of presentation

The accompanying condensed financial statements are unaudited and, in the opinion of Management, reflect all adjustments that are necessary for a fair presentation of the financial position and results of operations for the periods presented. All such adjustments are of a normal and recurring nature. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the entire year. The unaudited condensed financial statements should be read in conjunction with the financial statement disclosures contained in the Company’s audited financial statements incorporated into its Form 10-K filed on March 31, 2022 for the year ended December 31, 2021.

​

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. The amount reported as a contractual allowance for rebates involves examination of past historical trends related to sales to customers and the related credits issued once contractual obligations of the customers have been met. The establishment of a liability for future claims of rebates against sales in the current period requires that the Company has an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied.

Cash and cash equivalents

For purposes of reporting cash flows, cash and cash equivalents include cash, money market accounts, and investments with original maturities of three months or less.

Accounts receivable

The Company records trade receivables when revenue is recognized. No product has been consigned to customers. The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables. Those accounts that are doubtful of collection are included in the allowance. This provision is reviewed to determine the adequacy of the allowance for doubtful accounts. Trade receivables are charged off when there is certainty as to

5

Table of Contents

their being uncollectible. Trade receivables are considered delinquent when payment has not been made within contract terms. The Allowance for bad debt was $352,217 as of both September 30, 2022 and December 31, 2021.

The Company requires certain customers to make a prepayment prior to beginning production or shipment of their order. Customers may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders. Such amounts are included in Other accrued liabilities on the Condensed Balance Sheets and are shown in Note 6, Other Accrued Liabilities.

The Company records an allowance for estimated returns as a reduction to Accounts receivable and Gross sales. Historically, returns have been insignificant.

Receivable from Technology Investment Agreement (TIA)

The amounts set forth as Receivable from Technology Investment Agreement (TIA) represent amounts receivable under a contractual agreement under the TIA. The amounts may represent advance requests or reimbursement requests for expenditures the Company makes or has made under its obligations with the federal government. For further explanation, please refer to Note 15 – Technology Investment Agreement.

Inventories

Inventories are valued at the lower of cost or net realizable value, with cost being determined using actual average cost. The Company compares the average cost to the net realizable value and records the lower value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories. Once inventory items are deemed to be either excess or obsolete, they are written down to their net realizable value.

Investments in equity securities

The Company holds high-grade exchange-traded and closed-end funds (ETFs), mutual funds, and equity securities as investments. These assets are readily marketable and are carried at fair value as of the date of the Condensed Balance Sheets. Net unrealized and realized gains or losses on investments in equity securities are reflected separately on the Condensed Statements of Operations. Realized gains or losses on investments in equity securities are recognized using the specific identification method.

Property, plant, and equipment

Property, plant, and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. Cost includes major expenditures for improvements and replacements which extend useful lives or increase capacity and interest cost associated with significant capital additions. Gains or losses from disposals are included in Interest and other income.

The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:

​

​ | ​ | ​
Production equipment |  | 3 to 13 years
Office furniture and equipment |  | 3 to 10 years
Buildings |  | 39 years
Building improvements |  | 15 years

​

6

Table of Contents

Long-lived assets

The Company assesses the recoverability of long-lived assets using an assessment of the estimated undiscounted future cash flows related to such assets. In the event that assets are found to be carried at amounts which are in excess of estimated gross future cash flows, the assets will be adjusted for impairment to a level commensurate with fair value determined using a discounted cash flow analysis or appraised values of the underlying assets.

Fair value measurements

For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model.

Financial instruments

The Company estimates the fair value of financial instruments through the use of public market prices, quotes from financial institutions, and other available information. Judgment is required in interpreting data to develop estimates of fair value and, accordingly, amounts are not necessarily indicative of the amounts that could be realized in a current market exchange. Short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on Management's estimates, equals their recorded values. Investments in equity securities consist primarily of individual equity securities, exchange-traded and closed-end funds and mutual funds and are reported at their fair value based upon quoted prices in active markets. Investments in certificates of deposit (CD) with original maturities of greater than three months are reported at their estimated fair value based upon the duration of the CD and the interest rate earned on the CD versus current interest rates of similar duration CDs. The fair value of long-term liabilities, based on Management’s estimates, approximates their reported values.

Concentration risks

The Company’s financial instruments exposed to concentrations of credit risk consist primarily of cash, cash equivalents, certificates of deposit, exchange-traded and closed-end funds, mutual funds, equity securities, and accounts receivable. Cash balances, some of which exceed federally insured limits, are maintained in financial institutions; however, Management believes the institutions are of high credit quality. The Company assesses market risk in equity securities through consultation with its outside investment advisors. Management is responsible for directing investment activity based on current economic conditions. The majority of accounts receivable are due from companies which are well-established entities. Management considers any exposure from concentrations of credit risks to be limited.

The following table reflects significant customers for the three-month and nine-month periods ended September 30, 2022 and 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | Three Months Ended | ​ | ​ | Nine Months Ended | ​ | ​ | Nine Months Ended | ​
​ |  | September 30, 2022 |  | ​ | September 30, 2021 |  | ​ | September 30, 2022 |  | ​ | September 30, 2021 | ​
Number of significant customers |  | ​ | 2 |  | ​ | ​ | 2 |  | ​ | ​ | 4 |  | ​ | ​ | 1 |
Aggregate dollar amount of net sales to significant customers | ​ | $ | 15.5 | million | ​ | ​ | $ | 22.6 | million | ​ | ​ | $ | 60.0 | million | ​ | ​ | $ | 83.6 | million | ​
Percentage of net sales to significant customers | ​ | ​ | 67.4% | ​ | ​ | ​ | 62.1% | ​ | ​ | ​ | 73.0% | ​ | ​ | ​ | 64.8% | ​

​

7

Table of Contents

The Company manufactures some of its products in Little Elm, Texas as well as utilizing manufacturers in China. The Company obtained roughly 92.0% and 90.9% of its products in the first nine months of 2022 and 2021, respectively, from its Chinese manufacturers. Purchases from Chinese manufacturers aggregated 93.9% and 91.9% of products in the third quarter of 2022 and 2021, respectively. In the event that the Company becomes unable to purchase products from its Chinese manufacturers, the Company may need to find an alternate manufacturer for its blood collection set, IV catheter, Patient Safe® syringe, 0.5mL insulin syringe, 0.5mL autodisable syringe, and 2mL, 5mL, and 10mL syringes, and would increase domestic production for the 1mL and 3mL syringes and EasyPoint® needles.

Revenue recognition

The Company recognizes revenue when control of performance obligations passes to the customer, generally when the product ships. Payments from customers with approved credit terms are typically due 30 days from the invoice date. Under certain contracts, revenue is recorded on the basis of sales price to distributors, less contractual pricing allowances. Contractual pricing allowances consist of: (i) rebates granted to distributors who provide tracking reports which show, among other things, the facility that purchased the products, and (ii) a provision for estimated contractual pricing allowances for products for which the Company has not received tracking reports. When rebates are issued, they are applied against the customer’s receivable balance. Distributors receive a rebate for the difference between the Wholesale Acquisition Cost and the appropriate contract price as reflected on a tracking report provided by the distributor to the Company. If product is sold by a distributor to an entity that has no contract, there is a standard rebate (lower than a contracted rebate) given to the distributor. One of the purposes of the rebate is to encourage distributors to submit tracking reports to the Company. The provision for contractual pricing allowances is recognized in the period the related sales are recognized and is reviewed at the end of each quarter and adjusted for changes in levels of products for which there is no tracking report. Additionally, if it becomes clear that tracking reports will not be provided by individual distributors, the provision is further adjusted. The estimated contractual allowance is included in Accounts payable in the Condensed Balance Sheets and deducted from Revenues in the Condensed Statements of Operations. Accounts payable included estimated contractual allowances for $2.7 million and $6.2 million as of September 30, 2022 and December 31, 2021, respectively. The terms and conditions of contractual pricing allowances are governed by contracts between the Company and its distributors. Revenue for shipments directly to end-users is recognized when title and risk of ownership pass from the Company. End-users do not receive any contractual allowances on their purchases. Any product shipped or distributed for evaluation purposes is expensed.

The Company provides product warranties that: i) the products are fit for medical use as generally defined within the boundaries of United States FDA approval; ii) the products are not defective; and iii) the products will conform to the descriptions set forth in their respective labeling, provided that they are used in accordance with such labeling and the Company’s written directions for use. The Company has historically not incurred significant warranty claims.

The Company’s domestic return policy provides that a customer may return incorrect shipments within 10 days following arrival at the distributor’s facility. In all such cases, the distributor must obtain an authorization code from the Company and affix the code to the returned product. The Company’s domestic return policy also generally provides that a customer may return product that is overstocked. Overstocking returns are limited to two times in each 12-month period up to 1% of distributor’s total purchase of products for the prior 12-month period. All product overstocks and returns are subject to inspection and acceptance by the Company. The Company has historically not incurred significant returns.

The Company’s international distribution agreements generally do not provide for any returns.

The Company requires certain customers to pay in advance of product shipment. Such prepayments from customers are recorded in Other accrued liabilities and are generally recognized as revenue upon shipment of the product.

The Company periodically recognizes revenue from licensing agreements. If the Company licenses its products for sale and the customers of the sublicensee are not known to the Company, the Company is obligated to pay Thomas J.

8

Table of Contents

Shaw, the owner of certain patented technology, fifty percent (50%) of such revenue pursuant to the terms of the Technology License Agreement between the Company and Mr. Shaw.

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended September 30, 2022:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 6,947,856 | ​ | $ | 815,964 | ​ | $ | 1,426,060 | ​ | $ | 7,253 | ​ | $ | 9,197,133
Sales to U.S. government | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
North and South America sales (excluding U.S.) | ​ |  | 9,825,120 | ​ |  | — | ​ |  | — | ​ |  | 16,416 | ​ |  | 9,841,536
Other international sales | ​ |  | 3,915,102 | ​ |  | 8,590 | ​ |  | 97,724 | ​ |  | 1,200 | ​ |  | 4,022,616
Total | ​ | $ | 20,688,078 | ​ | $ | 824,554 | ​ | $ | 1,523,784 | ​ | $ | 24,869 | ​ | $ | 23,061,285

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended September 30, 2021:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales (excluding U.S. government) | ​ | $ | 11,033,291 | ​ | $ | 560,065 | ​ | $ | 4,048,292 | ​ | $ | 11,399 | ​ | $ | 15,653,047
Sales to U.S. government | ​ | ​ | 18,420,480 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 18,420,480
North and South America sales (excluding U.S.) | ​ |  | 670,602 | ​ |  | 4,800 | ​ |  | 26,400 | ​ |  | — | ​ |  | 701,802
Other international sales | ​ |  | 1,389,226 | ​ |  | 900 | ​ |  | 189,992 | ​ |  | 600 | ​ |  | 1,580,718
Total | ​ | $ | 31,513,599 | ​ | $ | 565,765 | ​ | $ | 4,264,684 | ​ | $ | 11,999 | ​ | $ | 36,356,047

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the nine months ended September 30, 2022:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales (excluding U.S. government) | ​ | $ | 22,220,324 | ​ | $ | 2,419,915 | ​ | $ | 4,294,603 | ​ | $ | 36,941 | ​ | $ | 28,971,783
Sales to U.S. government | ​ | ​ | 15,731,136 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 15,731,136
North and South America sales (excluding U.S.) | ​ |  | 24,421,790 | ​ |  | — | ​ |  | 2,608 | ​ |  | 232,834 | ​ |  | 24,657,232
Other international sales | ​ |  | 12,418,679 | ​ |  | 255,204 | ​ |  | 103,420 | ​ |  | 2,750 | ​ |  | 12,780,053
Total | ​ | $ | 74,791,929 | ​ | $ | 2,675,119 | ​ | $ | 4,400,631 | ​ | $ | 272,525 | ​ | $ | 82,140,204

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the nine months ended September 30, 2021:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales (excluding U.S. government) | ​ | $ | 30,685,338 | ​ | $ | 1,590,891 | ​ | $ | 7,019,560 | ​ | $ | 40,345 | ​ | $ | 39,336,134
Sales to U.S. government | ​ | ​ | 83,560,680 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 83,560,680
North and South America sales (excluding U.S.) | ​ |  | 2,963,930 | ​ | ​ | 4,800 | ​ | ​ | 83,248 | ​ | ​ | 109,440 | ​ |  | 3,161,418
Other international sales | ​ |  | 2,161,062 | ​ | ​ | 63,540 | ​ | ​ | 640,432 | ​ | ​ | 3,450 | ​ |  | 2,868,484
Total | ​ | $ | 119,371,010 | ​ | $ | 1,659,231 | ​ | $ | 7,743,240 | ​ | $ | 153,235 | ​ | $ | 128,926,716

​

9

Table of Contents

Income taxes

The Company evaluates tax positions taken or expected to be taken in a tax return for recognition in the financial statements based on whether it is “more-likely-than-not” that a tax position will be sustained based upon the technical merits of the position. Measurement of the tax position is based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.

The Company provides for deferred income taxes through utilizing an asset and liability approach for financial accounting and reporting based on the tax effects of differences between the financial statement and tax bases of assets and liabilities, based on enacted rates expected to be in effect when such differences reverse in future periods. Deferred tax assets are periodically reviewed for realizability. In prior periods, the Company established a valuation allowance for its net deferred tax asset as future taxable income which could not be reasonably assured. During the quarter ended June 30, 2020, the Company released its valuation allowance based on available evidence supporting that its deferred tax assets will be realized in full.

Earnings per share

The Company computes basic earnings per share (“EPS”) by dividing net earnings for the period (adjusted for any cumulative dividends for the period) by the weighted average number of common shares outstanding during the period. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect, if any, of the common stock deliverable pursuant to stock options and/or common stock issuable upon the conversion of convertible preferred stock.

The calculation of diluted EPS under the treasury stock method included the following shares in the three and nine month periods ending September 30, 2022 and 2021:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended
​ |  | September 30, 2022 |  | September 30, 2021 | ​ | September 30, 2022 |  | September 30, 2021
Common Stock underlying issued and outstanding stock options | ​ | 60,462 |  | 142,552 | ​ | 76,370 |  | 143,780
Common stock issuable upon the conversion of convertible preferred shares | ​ | 232,445 |  | 236,445 | ​ | 232,445 |  | 236,445
​ | ​ | 292,907 |  | 378,997 | ​ | 308,815 |  | 380,225

​

The potential dilution, if any, is shown on the following schedule:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended | ​
​ |  | September 30, 2022 |  | September 30, 2021 |  | September 30, 2022 |  | September 30, 2021 | ​
Net income | ​ | $ | 5,385,254 | ​ | $ | 6,521,885 | ​ | $ | 9,360,113 | ​ | $ | 35,139,894 | ​
Preferred stock dividend requirements | ​ |  | (58,111) | ​ |  | (59,111) | ​ |  | (174,333) | ​ |  | (183,219) | ​
Income applicable to common shareholders | ​ | $ | 5,327,143 | ​ | $ | 6,462,774 | ​ | $ | 9,185,780 | ​ | $ | 34,956,675 | ​
Average common shares outstanding | ​ |  | 32,936,959 | ​ |  | 33,883,684 | ​ |  | 33,049,411 | ​ |  | 33,950,742 | ​
Average common and common equivalent shares outstanding — assuming dilution | ​ |  | 33,229,866 | ​ |  | 34,262,681 | ​ |  | 33,358,225 | ​ |  | 34,330,967 | ​
Basic earnings per share | ​ | $ | 0.16 | ​ | $ | 0.19 | ​ | $ | 0.28 | ​ | $ | 1.03 | ​
Diluted earnings per share | ​ | $ | 0.16 | ​ | $ | 0.19 | ​ | $ | 0.28 | ​ | $ | 1.02 | ​

​

Shipping and handling costs

The Company classifies shipping and handling costs as part of Cost of sales in the Condensed Statements of Operations.

10

Table of Contents

Share-based Compensation

The Company’s share-based payments are accounted for using the Black-Scholes fair value method. The Company records share-based compensation expense on a straight-line basis over the requisite service period. The Company incurred share-based compensation costs of $1.1 million and $3.4 million in the three and nine months ended September 30, 2022, respectively, which were classified as General and administrative expenses.

​

Self-insured employee benefit costs

The Company self-insures certain health insurance benefits for its employees under certain policy limits. The Company has additional coverage provided by an insurance company for any individual with claims in excess of $100,000 and/or total plan claims in excess of $1.7 million for the plan year.

Research and development costs

Research and development costs are expensed as incurred.

Leases

The Company determines if an arrangement is a lease at inception. Operating and finance leases are included in Other assets, Other accrued liabilities, and Other long-term liabilities on the Condensed Balance Sheets. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the incremental borrowing rate based on information available at the commencement date was used in determining the present value of lease payments.

The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months or less are not recorded on the Condensed Balance Sheets; however, rent expense is recognized on a straight-line basis over the lease term.

Technology Investment Agreement (TIA)

Effective July 1, 2020, the Company entered into a Technology Investment Agreement (“TIA”) with the United States Government Department of Defense, U.S. Army Contracting Command-Aberdeen Proving Ground, Natick Contracting Division & Edgewood Contracting Division (ACC-APG, NCD & ECD) on behalf of the Biomedical Advanced Research and Development Authority (BARDA), as amended, for $81,029,518 in government funding for expanding the Company’s domestic production of needles and syringes. Pursuant to the terms of the TIA, the Company has made significant additions to its facilities which should allow the Company to increase domestic production. As reimbursements are received from the U.S. government for such expenditures, the Company records a deferred liability. In 2021, the deferred liability began to be systematically amortized as a gain over the life of the related property, plant, and equipment and is presented as Other income – TIA on the Condensed Statements of Operations.

Recently Adopted Pronouncements

The Company adopted ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance”. The new standard is intended to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. ASU 2021-10 also adds a new Topic – ASC 832, Government Assistance – to the FASB’s Codification. Included in the disclosures under the guidance are the nature of the transaction including the nature of the assistance being given, the accounting policies being used to account for the transaction and other provisions of

11

Table of Contents

relevance. The guidance is effective for annual periods beginning after December 15, 2021, with early adoption permitted. The Company has determined that the guidance did not have a material impact on its financial statements as such disclosures surrounding the TIA, including the accounting policies used to account for the agreement have been in place since its inception.

​

Recently Issued Pronouncements

In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, intended to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendment also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. ASU No. 2022-03 is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. For all other entities, it is effective for fiscal years, including interim periods within those fiscal years beginning after December 15, 2024. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the adoption of the amendments and the potential impact it may have, if any, on its financial statements.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”, to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients for contracts that reference LIBOR, if certain criteria are met, that can be applied through December 31, 2022. The Company has determined that the adoption of ASU No. 2020-04 would not have a material impact on its financial statements.

​

​

​

3. INVENTORIES

Inventories consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2022 |  | December 31, 2021
Raw materials | ​ | $ | 4,817,808 | ​ | $ | 4,402,828
Finished goods | ​ | ​ | 13,701,369 | ​ | ​ | 16,187,091
​ | ​ | $ | 18,519,177 | ​ | $ | 20,589,919

​

​

4. FAIR VALUE OF FINANCIAL INSTRUMENTS

ASC 820, “Fair Value Measurements”, defines fair value, establishes a framework for measuring fair value and requires additional disclosures regarding certain fair value measurements. ASC 820 establishes a three-tier hierarchy for measuring fair value, as follows:

| ● | Level 1 – quoted market prices in active markets for identical assets and liabilities

​

| ● | Level 2 – inputs other than quoted prices that are directly or indirectly observable

​

| ● | Level 3 – unobservable inputs where there is little or no market activity

​

12

Table of Contents

The following tables summarize the values of assets designated as Investments in equity securities:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2022
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Equity securities | ​ | $ | 24,458,406 | ​ | $ | — | ​ | $ | — | ​ | $ | 24,458,406
Mutual funds and exchange traded funds | ​ | ​ | 1,855,968 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,855,968
​ | ​ | $ | 26,314,374 | ​ | $ | — | ​ | $ | — | ​ | $ | 26,314,374

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2021
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Equity securities | ​ | $ | 9,112,607 | ​ | $ | — | ​ | $ | — | ​ | $ | 9,112,607
Mutual funds and exchange traded funds | ​ | ​ | 4,156,379 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,156,379
​ | ​ | $ | 13,268,986 | ​ | $ | — | ​ | $ | — | ​ | $ | 13,268,986

​

The Company holds high-grade ETFs, mutual funds, and individual equity stocks as investments. These assets are readily marketable and are carried at fair value as of the date of the Condensed Balance Sheets. The Company intends to hold these assets for possible future operating requirements. The following table summarizes gross unrealized gains and losses from Investments in equity securities:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2022
​ | ​ | ​ | ​ | ​ | Gross Unrealized | ​ | Aggregate
​ |  | Cost |  | Gains |  | Losses |  | Fair Value
Equity securities | ​ | $ | 22,866,864 | ​ | $ | 1,591,542 | ​ | $ | — | ​ | $ | 24,458,406
Mutual funds and exchange traded funds | ​ | ​ | 2,122,851 | ​ | ​ | — | ​ | ​ | (266,883) | ​ | ​ | 1,855,968
​ | ​ | $ | 24,989,715 | ​ | $ | 1,591,542 | ​ | $ | (266,883) | ​ | $ | 26,314,374

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2021
​ | ​ | ​ | ​ | ​ | Gross Unrealized | ​ | Aggregate
​ |  | Cost |  | Gains |  | Losses |  | Fair Value
Equity securities | ​ | $ | 6,729,245 | ​ | $ | 2,383,362 | ​ | $ | — | ​ | $ | 9,112,607
Mutual funds and exchange traded funds | ​ | ​ | 4,018,488 | ​ | ​ | 137,891 | ​ | ​ | — | ​ | ​ | 4,156,379
​ | ​ | $ | 10,747,733 | ​ | $ | 2,521,253 | ​ | $ | — | ​ | $ | 13,268,986

​

Unrealized gains (losses) on investments in equity securities were $(1.2) million and $816 thousand for the nine months ended September 30, 2022 and 2021, respectively.

​

​

​

5. INCOME TAXES

The Company’s effective tax rate on the net income (loss) before income taxes was 1,522.4% and 14.1% for the three months ended September 30, 2022 and 2021, respectively. The Company’s effective tax rate on the net income before income taxes was (19.8)% and 24.1% for the nine months ended September 30, 2022 and 2021, respectively

13

Table of Contents

A reconciliation of the federal statutory corporate tax rate to the Company’s effective tax rate is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​ | Nine Months Ended | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2022 |  | September 30, 2021 |  | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. statutory federal tax rate |  | 21.0 | % | 21.0 | % | ​ | ​ | ​ | ​ | ​ | ​ |
State tax, net of federal tax |  | 0.6 | % | 5.8 | % | ​ | ​ | ​ | ​ | ​ | ​ |
Stock options | ​ | 8.9 | % | (0.1) | % | ​ | ​ | ​ | ​ | ​ | ​ | ​
State tax nexus study | ​ | (89.5) | % | — | % | ​ | ​ | ​ | ​ | ​ | ​ | ​
State rate change | ​ | 34.3 | % | — | % | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other | ​ | 4.9 | % | (1.8) | % | ​ | ​ | ​ | ​ | ​ | ​ | ​
PPP loan | ​ | — | % | (0.8) | % | ​ | ​ | ​ | ​ | ​ | ​ | ​
Effective tax rate |  | (19.8) | % | 24.1 | % | ​ | ​ | ​ | ​ | ​ | ​ |

​

The Company uses the recognition and measurement provisions of the FASB ASC Topic 740, Income Taxes (“Topic 740”), to account for income taxes. The provisions of Topic 740 require a company to record a valuation allowance when the “more likely than not” criterion for realizing net deferred tax assets cannot be met. Furthermore, the weight given to the potential effect of such evidence should be commensurate with the extent to which it can be objectively verified. As a result, the Company reviewed the operating results, as well as all of the positive and negative evidence related to realization of such deferred tax assets to evaluate the need for a valuation allowance at September 30, 2022 and 2021.

The effective tax rate for the nine months ended September 30, 2022 was different from the federal statutory rate due primarily to stock-based compensation, an out of period adjustment due to compensation limits under IRC Section 162(m), and a change in the estimate of the apportionment of earnings across various state jurisdictions. In the third quarter of 2022, the Company, in conjunction with its state and local tax advisors, began a thorough analysis of the income tax imposition and apportionment statutes, including the application of Public Law 86-272. As a result of this analysis, the Company revised the estimates of deferred state income asset and current state income tax expense. The Company recorded a state income tax benefit of approximately $7 million in the third quarter of 2022. The effective tax rate for the nine months ended September 30, 2021 was different from the federal statutory rate due primarily to the apportionment of earnings across various state jurisdictions.

​

​

6. OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2022 |  | December 31, 2021
Prepayments from customers | ​ | $ | 676,843 | ​ | $ | 2,339,530
Accrued property taxes | ​ | ​ | 668,690 | ​ | ​ | —
Accrued professional fees | ​ | ​ | 254,608 | ​ | ​ | 185,515
Current portion – preferred stock repurchase | ​ |  | 1,084,795 | ​ |  | 1,098,282
Other accrued expenses | ​ |  | 160,736 | ​ |  | 102,200
Total | ​ | $ | 2,845,672 | ​ | $ | 3,725,527

​

​

7. OTHER LONG-TERM LIABILITIES

Other long-term liabilities consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2022 |  | December 31, 2021
Technology Investment Agreement (TIA) |  | $ | 75,006,588 |  | $ | 68,955,664
Stock repurchase |  | ​ | — |  | ​ | 1,040,666
Total | ​ | $ | 75,006,588 | ​ | $ | 69,996,330

​

The TIA provides for reimbursement to the Company for the purchase of equipment and supplies related to the expansion of the Company’s domestic production of needles and syringes. Under the TIA, reimbursable amounts will

14

Table of Contents

be reflected as a liability until the time its deferred income can be systematically amortized over a period matching the useful life of the purchased assets.

At December 31, 2021, the stock repurchase liability of amounts payable by the Company to former preferred shareholders as a result of private stock purchases in 2020 (See Note 12) was classified as a long-term liability. As of March 31, 2022, the final installment of $1,101,110 due in February 2023 was instead classified as Other accrued liabilities on the Condensed Balance Sheets.

​

8. COMMITMENTS AND CONTINGENCIES

On November 7, 2019, the Company filed a lawsuit in the 44th District Court of Dallas County, Texas (No. DC-19-17946) against Locke Lord, LLP and Roy Hardin in connection with their legal representation of the Company in its previous litigation against Becton, Dickinson and Company ("BD"). The Company alleged that the defendants breached their fiduciary duties, committed malpractice, and were negligent in their representation of the Company. The Company seeks actual and exemplary damages, disgorgement, costs, and interest. On October 6, 2020, the Court dismissed Locke Lord, LLP and Mr. Hardin’s motion to dismiss. Such order was affirmed on April 20, 2021 by the Court of Appeals, Fifth District of Texas at Dallas. On April 7, 2022, the Company amended its petition. On March 23, 2022 and again on May 4, 2022, Locke Lord, LLP and Mr. Hardin filed a motion for partial summary judgment regarding the Company’s cause of action for breach of fiduciary duty. On July 12, 2022, the Court granted a partial summary judgment and ordered that the Company take nothing on its cause of action for breach of fiduciary duty and ruled that such claims be characterized as professional negligence or legal malpractice causes of action. On August 3, 2022, Locke Lord, LLC and Mr. Hardin filed a motion for summary judgment regarding proximate cause and actual damages. On August 12, 2022, Locke Lord, LLC and Mr. Hardin filed a motion for summary judgment regarding Fifth Circuit law on patent infringement as antitrust conduct and such motion was denied on October 3, 2022. On September 2, 2022, the Company filed a Second Amended Petition alleging legal malpractice and negligence. A jury trial date of January 30, 2023 has been set for this case, but on November 8, 2022, the parties filed an Agreed Motion for Continuance which proposes that the trial date be reset to April 3, 2023.

​

9. BUSINESS SEGMENT

The Company does not operate in separate reportable segments. Shipments to international customers generally require a prepayment either by wire transfer or an irrevocable confirmed letter of credit. The Company does extend credit to international customers on some occasions depending upon certain criteria, including, but not limited to, the credit worthiness of the customer, the stability of the country, banking restrictions, and the size of the order. All transactions are in U.S. currency.

Revenues by geography are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Nine Months Ended | ​ | Nine Months Ended | ​
​ |  | September 30, 2022 |  | September 30, 2021 |  | September 30, 2022 |  | September 30, 2021 | ​
U.S. sales (excluding U.S. government) | ​ | $ | 9,197,133 | ​ | $ | 15,653,047 | ​ | $ | 28,971,783 | ​ | $ | 39,336,134 | ​
Sales to U.S. government | ​ | ​ | — | ​ | ​ | 18,420,480 | ​ | ​ | 15,731,136 | ​ | ​ | 83,560,680 | ​
North and South America sales (excluding U.S.) | ​ |  | 9,841,536 | ​ |  | 701,802 | ​ |  | 24,657,232 | ​ |  | 3,161,418 | ​
Other international sales | ​ |  | 4,022,616 | ​ |  | 1,580,718 | ​ |  | 12,780,053 | ​ |  | 2,868,484 | ​
Total sales | ​ | $ | 23,061,285 | ​ | $ | 36,356,047 | ​ | $ | 82,140,204 | ​ | $ | 128,926,716 | ​

​

15

Table of Contents

Long-lived assets by geography are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, 2022 |  | December 31, 2021 | ​
Long-lived assets | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. | ​ | $ | 94,171,727 | ​ | $ | 83,695,991 | ​
International | ​ | ​ | 4,649,685 | ​ | ​ | 4,229,660 | ​
Total | ​ | $ | 98,821,412 | ​ | $ | 87,925,651 | ​

​

​

​

10. DIVIDENDS

In January 2021, a cash dividend payment of $10,041 was made to Series I preferred shareholders. The Company caused a redemption of its Series I preferred stock on December 31, 2020 pursuant to the terms of the Certificate of Designation for such series.

​

A cash dividend of $39,050 was paid in January 2021, April 2021, October 2021, January 2022, April 2022, July 2022, and October 2022 to Series II preferred shareholders. Series III preferred shareholders were paid $39,495 in January 2022 and $19,061 in April 2022, July 2022, and October 2022.

​

In June 2021, the Board of Directors approved payments to its Series II, Series III, and former Series IV and Series V Class B Preferred Shareholders in the cumulative amount of $5,056,945 representing all current dividends, dividends in arrears, as well as dividends still owed to shareholders who converted their preferred stock in the past. The dividends were paid on July 22, 2021 to all shareholders who had been contacted and confirmed as the rightful owner entitled to payment. The Company has not yet established contact with all former shareholders, most of whom converted their shares prior to 2001. As of November 1, 2022, the Company is continuing its efforts to establish contact with approximately 90 former shareholders who are entitled to approximately $1.4 million. This, along with the current declared dividends, are reflected in Dividends payable on the Condensed Balance Sheets.

​

11. TREASURY STOCK

In June 2021, the Company approved a stock repurchase plan as described by Note 16. The Company accounts for the purchased shares under the cost method as Common Stock Held in Treasury – at cost, which represents the cost of the shares and the cost of acquiring the shares through the Company’s broker.

​

​

​

12. EXCHANGE OF COMMON STOCK FOR PREFERRED STOCK

In 2020, the Company entered into several agreements with shareholders to purchase its outstanding Class B Convertible Preferred Stock. The consideration for these purchases consisted of both cash and Common Stock. In addition, in each such transaction, the preferred shareholder counterparty waived all rights to unpaid dividends in arrears. The aggregate cash consideration equaled $3,786,000, of which $482,670 was paid in 2020. The balance is payable over a three-year period which began in February 2021. In February 2022 and 2021, the Company paid the first two of three equal installments of $1,101,110.

​

13. STOCK OPTIONS

Stock options were exercised by an employee and a director in the nine months ended September 30, 2022, and, consequently, a total of 11,200 shares of Common Stock were issued for an aggregate payment to the Company of $13,800 to exercise such options.

14. PAYCHECK PROTECTION PROGRAM LOAN

On April 17, 2020, the Company entered into a promissory note in the principal amount of $1,363,000 (the “PPP Loan”) in favor of Independent Bank pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), administered by the U.S. Small Business Administration (“SBA”). The PPP Loan’s original maturity date was April 17, 2022 with an interest rate of 1.0% per annum. The PPP

16

Table of Contents

Loan had a prepayment option with no prepayment penalties. The PPP Loan was unsecured and was a non-recourse obligation.

On May 13, 2021, the Company was informed that the SBA granted its request for loan forgiveness for the entire original principal and accrued interest, for a total of $1,377,652. No payments were made prior to receiving forgiveness.

15. TECHNOLOGY INVESTMENT AGREEMENT

Effective July 1, 2020, the Company entered into the TIA with the U.S. government to expand the Company’s manufacturing capacity for hypodermic safety needles in response to the worldwide COVID-19 global pandemic. The award is an expenditure-type TIA, whereby the U.S. government will make payments to the Company for the Company’s expenditures for equipment and supplies related to the expansion. The Company’s contributions under the terms of the TIA include providing facilities, technical expertise, labor and maintenance for the TIA-funded equipment for a ten-year term. In May of 2021, the Company and the U.S. government amended the TIA agreement to include two additional assembly lines and additional controlled environment space. The TIA and its amendment provide up to $53.7 million and $27.3 million respectively, or $81 million in total reimbursements.

As of September 30, 2022, the Company had negotiated contracts for the purchase of assembly equipment, molds, molding equipment, and auxiliary equipment, for approximately $66.2 million. A temporary certificate of occupancy has been received for the additional $13 million controlled environment space. In addition, the Company has received the certificate of occupancy for the new warehouse. This $5.9 million warehouse was funded by the Company.

16. STOCK REPURCHASE PLAN

The Company entered into a repurchase plan (the “Plan”) dated June 4, 2021 with an independent broker for the purchase of up to $10 million of the Company’s Common Stock. The treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s balance sheets. The Plan was terminated on April 14, 2022. A total of 1,087,145 shares were purchased under the Plan for a total purchase price of $8.1 million.

​

Of the 100 million authorized shares of Common Stock, 34,024,304 shares were issued and 32,937,159 shares were outstanding as of September 30, 2022. There were 34,023,104 shares issued and 33,484,935 shares outstanding as of December 31, 2021.

​

​

​

​

​

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENT WARNING

Certain statements included by reference in this filing containing the words “could,” “may,” “believes,” “anticipates,” “intends,” “expects,” and similar such words constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Any forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others: the impact of supply chain and transportation delays on all facets of logistics and operations as well as costs; our ability to scale up production volumes in response to an increase in demand; potential tariffs; our ability to maintain liquidity; our maintenance of patent protection; our ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; our ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and any other factors referenced in Item 1A. Risk Factors in Part II. Given these uncertainties, undue reliance should not be placed on forward-looking statements.

17

Table of Contents

MATERIAL CHANGES IN FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We have been manufacturing and marketing our products since 1997. VanishPoint® syringes comprised 91.1% of our sales in the first nine months of 2022. EasyPoint® products accounted for 5.4% of sales in the first nine months of 2022. We also manufacture and market an IV safety catheter and blood collection products, including the blood collection tube holder and VanishPoint® Blood Collection Set, which were 3.3% of our total product sales for the first nine months of 2022.

Our products have been and continue to be distributed nationally and internationally through numerous distributors. Some of our popular syringe products provide low dead-space. Low dead-space syringes reduce residual medication remaining in the syringe after the dose has been administered. In some instances, the low dead-space allows for additional doses of medication to be obtained from the vials. We plan to highlight the advantages of our low dead-space products, including the potential to reduce the costs associated with wasted medication, as part of our overall marketing message.

On May 1, 2020, we were awarded a delivery order under an existing contract by the Department of Health and Human Services of the United States to supply automated retraction safety syringes for COVID-19 vaccination efforts, which order was in the amount of $83.8 million plus $10 million in expedited freight costs. The period of performance for this order ended in March 2022.

The Department of Health and Human Services awarded us another contract on February 12, 2021 to supply low dead-space safety syringes for COVID-19 vaccination efforts. The base price for the contract and purchase order was $54.2 million for the five-month base period of performance (February 15, 2021 to July 14, 2021). We received non-binding notice that the contract would be extended for seven additional months beyond the base period of performance. However, to date, we have not received additional orders beyond the first four option periods which extended through the end of December 2021. For each period, the freight reimbursement cost was included in total overall contract value and was approximately 25% of the overall price.

Our sales under both of the foregoing orders from the U.S. government were $15.7 million during the first three months of 2022, representing 19.2% of our total sales for the nine-months ended September 30, 2022, but no sales were made to the U.S. government in the second or third quarter of 2022. Both of the above-mentioned orders as well as the TIA (as defined below) from the U.S. government are material events particular to the COVID-19 pandemic and may not be indicative of future operations. While we continue to work with the Department of Health and Human Services, additional orders are uncertain. Our second and third quarter 2022 revenues materially declined as compared with other recent periods due to the absence of U.S. government orders. Recent additions of manufacturing equipment and facilities have increased our production capacity. However, in the absence of significant demand, such capacity may be underutilized. For instance, in the second and third quarter of 2022, with lower demand and high volumes of finished goods on hand, production levels declined despite the increase in production capacity.

Effective July 1, 2020, we entered into a Technology Investment Agreement (“TIA”) with the United States Government Department of Defense, U.S. Army Contracting Command-Aberdeen Proving Ground, Natick Contracting Division & Edgewood Contracting Division (ACC-APG, NCD & ECD) on behalf of the Biomedical Advanced Research and Development Authority (BARDA) for $53.7 million in government funding for expanding our domestic production of needles and syringes to meet ongoing and future U.S. COVID-19 medical countermeasures demands. Effective May 12, 2021, we entered into an amendment to the TIA providing an additional $27.4 million in funding to include two additional assembly lines and additional controlled environment space. As of September 30, 2022, we have negotiated contracts for the purchase of automated assembly equipment, molds, and molding equipment, as well as portions of auxiliary equipment, for approximately $66.2 million. We have also received a temporary certificate of occupancy for the $13 million additional controlled environment spaces. Finally, we have received the certificate of occupancy for the new $5.9 million 55,000 square foot warehouse, which is our financial responsibility.

18

Table of Contents

The closure of the Shanghai ports in the second quarter of 2022 reduced the volume of products shipped to us and our international customers from our Chinese manufactures in the second quarter. Consequently, these deliveries were delayed until the third quarter and represented approximately 34% of third quarter international sales.

Higher freight costs have continued through the third quarter of 2022. The increase in freight costs has significantly impacted our cost of manufactured product, and we expect this trend to continue. These cost increases are not unique to our business, but the fact that a substantial percent of our prior period sales were related to orders from the U.S. government with reimbursed freight costs will affect comparability of 2022 costs and margins to prior periods. Other factors that could affect our unit costs include increases in tariffs, supplier cost increases, and changing production volumes. Increases in costs may not be recoverable through price increases of our products.

Other factors which could have a material impact on our business include COVID-19 booster shot recommendations, flu shot campaigns, and inefficient domestic distribution networks. We believe that other viruses aside from COVID-19 have the potential to impact future sales, including, but not limited to, a potentially strong flu virus this year. COVID-19 booster shots have been recommended to the public, but we believe that many facilities still have excess inventory of vaccination materials on hand, including syringes.

The expansion of our existing administrative offices by 14,000 square feet at a cost of $5.8 million is expected to be completed in late November 2022.

As detailed in Note 4 to the financial statements, we held $26.3 million in equity securities as of September 30, 2022, which represented 28.7% of our current assets. Such amount includes unrealized losses on investments, as well as an additional $2.0 million cash investment during the first quarter of 2022 and $12 million during the second quarter of 2022. We continually monitor our invested balances.

​

In response to, among other factors, the global COVID-19 pandemic, our delivery orders from the U.S. government, and the TIA, employee headcount and related salary and benefits costs increased significantly during 2020 and 2021. In June 2022, we reduced our workforce by approximately 16% as a result of the substantial completion of our facility expansion efforts and the completion of U.S. government orders to provide products for COVID-19 vaccination efforts. As of September 30, 2022, the Company employed approximately 204 full-time, part-time, and temporary employees. Compensation costs decreased 6.4%. As a result of our completion of the original U.S. government delivery orders and the progression of the TIA, we continue to monitor our current level of operating expenses, including the overall impact of our staffing structure.

Effective June 4, 2021, we entered into a repurchase plan (the “Plan”) for the purchase of up to $10 million of our Common Stock. Under the Plan, open market purchases of our Common Stock commenced June 18, 2021 and 1,087,145 shares were purchased through the Plan’s termination on April 14, 2022 for an aggregate purchase price of approximately $8.1 million. We terminated the plan because our stock price appeared not to be correlated with our economic performance.

Historically, unit sales have increased during the flu season. Seasonal trends in 2020 and 2021 were less pronounced due to demand related to the COVID-19 vaccine. With the completion of our delivery orders from the U.S. government, flu season orders may have a more pronounced effect on 2022 revenues.

Product purchases from our Chinese manufacturers have enabled us to increase manufacturing capacity with little capital outlay and have provided a competitive manufacturing cost. In the third quarter of 2022, our Chinese manufacturers produced approximately 94% of our products. In the event that we become unable to purchase products from our Chinese manufacturers, we may need to find an alternate manufacturer for the blood collection set, IV catheter, Patient Safe® syringe, 0.5mL insulin syringe, 0.5mL autodisable syringe, and 2mL, 5mL, and 10mL syringes and we would increase domestic production for the 1mL and 3mL syringes and EasyPoint® needles.

In 1995, we entered into a license agreement with Thomas J. Shaw for the exclusive right to manufacture, market, and distribute products utilizing his patented automated retraction technology and other patented technology. This technology is the subject of various patents and patent applications owned by Mr. Shaw. The license agreement generally

19

Table of Contents

provides for quarterly payments of a 5% royalty fee on gross sales of products subject to the license and he receives fifty percent (50%) of the royalties paid to us by certain sublicensees of the technology subject to the license.

RESULTS OF OPERATIONS

The following discussion may contain trend information and other forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ materially from our historical results of operations and those discussed in any forward-looking statements. All period references are to periods ended September 30, 2022 or 2021, as applicable. Dollar amounts have been rounded for ease of reading.

​

Comparison of Three Months Ended September 30, 2022 and September 30, 2021

Domestic sales accounted for 39.9% and 93.7% of the revenues for the three months ended September 30, 2022 and 2021, respectively. Domestic revenues decreased 73.0% principally due to the lack of third quarter sales to the U.S. government. Domestic unit sales decreased 71.6%. Domestic unit sales were 29.0% of total unit sales for the three months ended September 30, 2022. International revenues increased approximately 507.4% predominantly due to international vaccination campaigns. Overall unit sales decreased 11.3%. There is uncertainty as to the timing of future international orders. The revenues on a per-unit basis in the international market are significantly lower than in the U.S. market. As a result, increases in international orders and unit sales have the potential to lower our overall revenues on a per-unit basis, as well as our profit margins.

Cost of manufactured product decreased 18.5% principally due to lower volumes. Royalty expense decreased 35.2% due to decreased gross sales.

Operating expenses were largely unchanged from the prior year.

The loss from operations was $691 thousand compared to income from operations of $8.0 million for the same period last year. The decrease was due to an overall decrease in revenues and because per-unit costs have risen with lower production levels.

The unrealized loss on equity securities was $615 thousand due to the decreased market values of those securities. Interest expense for the third quarter of 2022 decreased by approximately 23.8% from the same period in the prior year due to less imputed interest associated with the stock exchanges discussed in Note 12 of the financial statements.

The benefit for income taxes was $5.8 million for the third quarter of 2022 in comparison to the provision for income taxes of $1.1 million in the third quarter of 2021.

Comparison of Nine Months Ended September 30, 2022 and September 30, 2021

Domestic sales, including sales to the U.S. government, accounted for 54.4% and 95.3% of the revenues for the nine months ended September 30, 2022 and 2021, respectively. Domestic revenues decreased 63.6% principally due to lower sales to the U.S. government. Domestic unit sales decreased 65.5%. Domestic unit sales were 40.7% of total unit sales for the nine months ended September 30, 2022. Domestic unit sales excluding the U.S. government sales decreased approximately 38.2%. International revenues increased approximately 520.9% predominantly due to international vaccination campaigns. Overall unit sales decreased 21.4%. There is uncertainty as to the timing of future international orders. The revenues on a per-unit basis in the international market are significantly lower than in the U.S. market. As a result, increases in international orders and unit sales have the potential to lower our overall revenues on a per-unit basis, as well as our profit margins.

Cost of manufactured product decreased 11.4% principally due to lower volumes. Royalty expense decreased 36.5% due to decreased gross sales.

Operating expenses were largely unchanged from the prior year.

20

Table of Contents

Income from operations was $7.0 million compared to income from operations of $44.1 million for the same period last year. The decrease was due to an overall decrease in revenues and because per-unit costs have risen with lower production levels.

The unrealized loss on equity securities was $1.2 million due to the decreased market values of those securities. Interest expense for the first nine months of 2022 decreased by approximately 27.2% from the same period in the prior year due to less imputed interest associated with the stock exchanges discussed in Note 12 of the financial statements.

The first nine months of 2022 reflected a $1.5 million benefit for income taxes as opposed to a provision of $11.1 million for the first nine months of 2021.

Discussion of Balance Sheet and Cash Flow Items

​

Cash comprises 6.7% of total assets. Cash flow from operations was $6.6 million for the nine months ended September 30, 2022 principally due to the collection of accounts receivable. Additionally, we have recorded deferred taxes of $3.9 million which is material to the adjustments to total cash flow from operations. The deferred tax asset represents amounts available to reduce income taxes payable on taxable income in future years.

​

Cash used by investing activities was $28.2 million for the nine months ended September 30, 2022 due primarily to the purchase of property, plant and equipment, building improvements, and the purchase of equity securities. The impact to cash from the purchase of fixed assets primarily reflects down payments on orders for certain assets as discussed in Note 15 to the financial statements.

Cash provided by financing activities was $5.8 million for the nine months ended September 30, 2022. This was primarily due to proceeds from the government under the TIA for down payments on our orders for fixed assets, but was offset by our repurchase of common stock in the first half of 2022 in the amount of $2.8 million as well as our payment of $1.1 million in connection with the stock exchange discussed in Note 12.

LIQUIDITY AND CAPITAL RESOURCES

Internal Sources of Liquidity

We have historically funded operations primarily from the proceeds from revenues, private placements, litigation settlements, and loans. We expect to fund operations going forward from revenues, cash reserves, and investments available for sale if the need to access those funds arises. We do not, and historically have not, utilized lines of credit to fund operations.

Margins

The mix of domestic and international sales affects the average sales price of our products. Generally, the higher the ratio of domestic sales to international sales, the higher the average sales price will be. Some international sales of our products are shipped directly from China to the customer. The number of units produced by us versus manufactured in China can have a significant effect on the carrying costs of Inventory as well as Cost of sales. Generally, an overall increase in units sold can positively affect our margins. The cost of raw materials used in manufacturing and transportation costs can also significantly affect our margins. We will continue to evaluate the appropriate mix of products manufactured domestically and those manufactured in China to achieve economic benefits as well as to maintain our domestic manufacturing capability.

Cash Requirements

We believe we will have adequate means to meet our short-term needs to fund operations for at least 12 months. Besides cash reserves and expected income from operations, we also have access to our investments which may be liquidated in the event that we need to access the funds for operations. Expected short-term uses of cash include payroll and benefits, royalty expense, inventory purchases, contractual obligations, capital expenditures, payment of income taxes,

21

Table of Contents

quarterly preferred stock dividends, and other operational priorities. Our long-term plans involving material cash requirements for capital expenditures are detailed in this section below under “Capital Resources” and our liabilities are our bank debt as set forth as out Long-term debt on our Condensed Balance Sheets and other liabilities detailed herein in Note 7 to the financial statements. We believe we will have adequate means to meet our currently foreseeable long-term liquidity needs. In the event that our long-term cash requirements exceed our current reserves and our ability to generate cash from operations, management would necessarily undertake to reduce our operational cash requirements.

Contracts with the U.S. Government

As discussed above, we were awarded a material delivery order by the Department of Health and Human Services of the United States in the total amount of approximately $83.8 million, plus certain expedited freight expenses. In February 2021, we received another material contract from the Department of Health and Human Services for additional safety syringes representing expected revenues and reimbursable freight costs of $54.2 million for a five-month period ending July 14, 2021 and an initial indication of commitment for seven additional monthly option periods. To date, we have not received additional orders beyond the first four option periods which extended through December 2021. While we continue to work with the Department of Health and Human Services, significant future orders are uncertain.

As discussed above, we entered into a TIA with the U.S. government for a total value of approximately $81.0 million in government funding for expanding our domestic production of needles and syringes. As of September 30, 2022, we have received approximately $75.5 million for down payments on the purchase of certain fixed assets.

External Sources of Liquidity

We received a PPP Loan in the principal amount of $1.4 million. On May 13, 2021, we were informed that the entire original principal amount of $1.4 million would be forgiven.

We consider our investment portfolio a source of liquidity as well. As of September 30, 2022, $26.3 million was invested in third party securities.

Capital Resources

Since the execution of the TIA on July 1, 2020, we have significantly expanded our facilities. These TIA expenditures are generally reimbursable by the U.S. government and discussed elsewhere in this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Other than the TIA expenditures, the only ongoing capital project is the completion of the expansion to our administrative offices by 14,000 square feet. Our remaining financial obligation for that project is approximately $650 thousand as of November 4, 2022.

CRITICAL ACCOUNTING ESTIMATES

We are responsible for developing estimates for amounts reported as assets and liabilities, and revenues and expenses in conformity with U.S. generally accepted accounting principles (“GAAP”). Those estimates require that we develop assumptions of future events based on past experience and expectations of economic factors. Among the more critical estimates management makes is the estimate for customer rebates. The amount reported as a contractual allowance for rebates involves examination of past historical trends related to our sales to customers and the related credits issued once contractual obligations of the customers have been met. The establishment of a liability for future claims of rebates against sales in the current period requires that we have an understanding of the relevant sales with respect to product categories, sales distribution channels, and the likelihood of contractual obligations being satisfied. We examine the results of estimates against actual results historically and use the determination to further develop our basis for assumptions in future periods, as well as the accuracy of past estimates. While we believe that we have sufficient historical data, and a firm basis for establishing reserves for contractual obligations, there is an inherent risk that our estimates and the underlying assumptions may not reflect actual future results. In the event that these estimates and/or assumptions are incorrect, adjustments to our reserves may have a material impact on future results.

​

22

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

​

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, Management, with the participation of our President, Chairman, and Chief Executive Officer, Thomas J. Shaw (the “CEO”), and our Vice President and Chief Financial Officer, John W. Fort III (the “CFO”), acting in their capacities as our principal executive and principal financial officers, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. The term disclosure controls and procedures means controls and other procedures that are designed to ensure that information required to be disclosed by us in our periodic reports is: i) recorded, processed, summarized, and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms; and ii) accumulated and communicated to our Management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based upon this evaluation, the CEO and CFO concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There have been no changes during the third quarter of 2022 or subsequent to September 30, 2022 in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

​

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

Please refer to Note 8 to the financial statements for a complete description of all legal proceedings.

Item 1A. Risk Factors.

There were no material changes in our Risk Factors as set forth in our most recent annual report which is available on EDGAR.

​

23

Table of Contents

Item 6. Exhibits.

​ | ​ | ​
Exhibit No. |  | Description of Document
​ | ​ | ​
31.1 | ​ | Certification of Principal Executive Officer
​ | ​ | ​
31.2 | ​ | Certification of Principal Financial Officer
​ | ​ | ​
32 | ​ | Certification Pursuant to 18 U.S.C. Section 1350
​ | ​ | ​
101 | ​ | The following materials from Retractable Technologies, Inc.’s Form 10-Q for the period ended September 30, 2022, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Condensed Balance Sheets as of September 30, 2022 and December 31, 2021, (ii) Condensed Statements of Operations for the three and nine months ended September 30, 2022 and 2021, (iii) Condensed Statements of Cash Flows for the nine months ended September 30, 2022 and 2021, (iv) Condensed Statement of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021; and (v) Notes to Condensed Financial Statements
​ | ​ | ​
104 | ​ | Interactive Data File (formatted Inline XBRL and contained in Exhibit 101)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

DATE: November 14, 2022 | RETRACTABLE TECHNOLOGIES, INC.
​ | (Registrant)
​ | ​ | ​
​ | ​ | ​
​ | By: | /s/ John W. Fort III
​ | ​ | JOHN W. FORT III VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER

​

​

​

​

24